Related Experiment Video

Updated: Feb 1, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Three May Be Better Than Two: A Proposal for Metformin Addition to PI3K/Akt Inhibitor-antiandrogen Combination in

Mohamed Islam Delma1

  • 1Endocrinology, Colonel Chaabani Hospital, El Menia, DZA.

Cureus
|December 12, 2018
PubMed

Insights

Metformin may enhance prostate cancer treatment by targeting pathways shared with antiandrogens and PI3K/Akt inhibitors. This research hypothesizes metformin addition optimizes dual blockade therapy for castration-resistant prostate cancer (CRPC).

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Background:

  • Prostate cancer is a common malignancy.
  • Castration-resistant prostate cancer (CRPC) presents a poor prognosis due to resistance to androgen deprivation therapy.
  • Current research focuses on novel therapeutics for this refractory state.

Purpose of the Study:

  • To review the effects of metformin on prostate cancer.
  • To explore metformin's shared therapeutic targets with antiandrogens and PI3K/Akt inhibitors.
  • To hypothesize metformin's role in optimizing dual blockade therapy for CRPC.

Main Methods:

  • Literature review on metformin's mechanisms in prostate cancer.
  • Analysis of shared therapeutic targets between metformin, antiandrogens, and PI3K/Akt inhibitors.
  • Deduction of a hypothesis for combination therapy.

Main Results:

  • Metformin exhibits effects on prostate cancer relevant to current treatment strategies.
  • Identified shared molecular targets between metformin and other CRPC therapies.
  • Established a rationale for investigating metformin in combination therapy.

Conclusions:

  • Metformin's properties suggest potential as an adjunct therapy in CRPC.
  • Combination therapy involving metformin, antiandrogens, and PI3K/Akt inhibitors warrants further investigation.
  • Optimizing dual blockade strategies with metformin could improve CRPC treatment outcomes.
Keywords:
castration-resistant prostate cancermetforminpi3k/akt inhibitors

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.6K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Conjugate Addition (1,4-Addition) vs Direct Addition (1,2-Addition)01:27

Conjugate Addition (1,4-Addition) vs Direct Addition (1,2-Addition)

α,β-Unsaturated carbonyl compounds with two electrophilic sites, the carbonyl carbon, and the β carbon, are susceptible to nucleophilic attack via two modes: conjugate or 1,4-addition and direct or 1,2-addition.
Conjugate addition results in a thermodynamically stable product. The reaction retains the stronger C=O bond at the expense of the weaker C=C π bond. The process is slow as the β carbon is less electrophilic than the carbonyl carbon.
Direct addition products are...
4.3K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Conjugate Addition of Enolates: Michael Addition01:08

Conjugate Addition of Enolates: Michael Addition

The attack of a nucleophile at the β carbon of an α,β-unsaturated carbonyl compound is called conjugate addition. Conjugate addition reactions of active methylene compounds, such as β-diketones, β-keto esters, β-keto nitriles, and α-nitro ketones, are called Michael addition reactions.
3.6K
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.6K